2024
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review
Patel A, Laine L, Moayyedi P, Wu J. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology 2024, 167: 1228-1238. PMID: 39269391, DOI: 10.1053/j.gastro.2024.06.038.Peer-Reviewed Original ResearchPotassium-competitive acid blockerClinical Practice UpdateFirst-line therapyProton pump inhibitorsTwice-daily proton pump inhibitorBest practice advice statementsPractice advice statementsPeptic ulcer diseaseErosive esophagitisHeartburn symptomsAmerican Gastroenterological Association (AGA) Institute Clinical Practice UpdateClinical superiorityDouble-dose PPIsDouble-dose proton pump inhibitorsProphylaxis of peptic ulcer diseaseReflux diseaseStandard-dose PPIUlcer diseaseExpert reviewStandard procedures of GastroenterologyHigh-risk stigmataAcid inhibitionOn-demand therapyMaintenance of healingBleeding gastroduodenal ulcers
2010
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies. Alimentary Pharmacology & Therapeutics 2010, 33: 203-212. PMID: 21114792, DOI: 10.1111/j.1365-2036.2010.04516.x.Peer-Reviewed Original ResearchConceptsHeartburn resolutionErosive oesophagitisExtended releaseLA grade CSevere erosive oesophagitisDouble-blind trialDouble-blind studyPossibility of benefitCurrent PPIsD oesophagitisSevere oesophagitisGERD patientsSecondary endpointsPrimary endpointSymptomatic resolutionAcid suppressionSubgroup analysisDrug exposureClinical trialsOesophagitisGrade DGrade CFurther evaluationEsomeprazoleAcid inhibition
1995
Retinoic acid inhibition of transforming growth factor-beta-induced collagen production by human lung fibroblasts.
Redlich C, Delisser H, Elias J. Retinoic acid inhibition of transforming growth factor-beta-induced collagen production by human lung fibroblasts. American Journal Of Respiratory Cell And Molecular Biology 1995, 12: 287-295. PMID: 7873195, DOI: 10.1165/ajrcmb.12.3.7873195.Peer-Reviewed Original ResearchConceptsHuman lung fibroblastsRetinoic acidCollagen productionChronic inflammatory lung disordersDoses of RALung fibroblastsType IInhibitory effectInflammatory lung disordersTrans retinoic acidFibroblast collagen productionM retinoic acidLung disordersPotent immunomodulatorFibrotic responseRetinoid compoundsType III collagenBasal levelsSignificant inhibitionAcid inhibitionSignificant decreaseRetinoidsUnstimulated cellsPreincubationStimulation
1987
Properties of the canalicular bile acid transport system in rat liver
Meier P, Meier-Abt A, Boyer J. Properties of the canalicular bile acid transport system in rat liver. Biochemical Journal 1987, 242: 465-469. PMID: 3593261, PMCID: PMC1147728, DOI: 10.1042/bj2420465.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply